Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that
is reimagining therapeutic delivery, today announced that its
BioJet™ Systemic Oral Delivery Platform has met key performance
milestones as part of its research collaboration with AstraZeneca.
The BioJet platform is designed to use needle-free, liquid jet
injection to deliver drug into the small intestine for systemic
absorption.
“In a preclinical study, we assessed the bioavailability of our
collaborator’s molecule when delivered via our BioJet device in a
porcine model, with comparison to subcutaneous administration.
BioJet devices were administered endoscopically, which is typical
in a porcine model, and released for autonomous activation,” said
Sharat Singh, PhD, Head of Research at Biora Therapeutics. “We are
encouraged by the results, which met our performance targets of
greater than 25% bioavailability compared to subcutaneous delivery,
and less than 50% coefficient of variation.”
“We continue to generate very promising results with our BioJet
platform, including those from this study, which are enabling us to
progress development under the collaboration,” said Adi Mohanty,
Chief Executive Officer of Biora Therapeutics. “While many
organizations have been working to solve the challenge of oral
delivery of large molecules, we believe our approach stands out
because of our ability to deliver multi-milligram liquid doses
similar to injection, with minimal to no formulation changes.”
Biora has previously presented data generated from other
molecules with the BioJet platform in animal models, which can be
viewed at bioratherapeutics.com/publications.
About the BioJet™ Systemic Oral Delivery
Platform Biora's BioJet systemic oral therapeutics
platform uses an ingestible capsule for needle-free, oral delivery
of large molecules designed to achieve systemic bioavailability and
replace injection for better management of chronic
diseases.
The BioJet platform uses an ingestible device designed to
transit through the digestive system and activate in the small
intestine, where liquid jets deliver drug directly into the small
intestine for uptake into systemic circulation. The BioJet device
is approximately the size of a multivitamin and is designed to
autonomously deliver a wide range of large molecules, such as
proteins, peptides, and nucleic acids, in liquid formulation at
multi-milligram doses, without requiring complex
reformulation.
Biora holds a comprehensive patent position for the BioJet
systemic oral delivery platform, with approximately 12 issued
patents and 29 pending applications that cover its delivery
platform and methods for using the platform to treat a disease or
condition in a patient using liquid jet delivery of a wide range of
drugs.
About Biora TherapeuticsBiora Therapeutics is
reimagining therapeutic delivery. By creating innovative smart
pills designed for targeted drug delivery to the GI tract, and
systemic, needle-free delivery of biotherapeutics, the company is
developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics platforms:
the NaviCap™ targeted oral delivery platform, which is designed to
improve outcomes for patients with inflammatory bowel disease
through treatment at the site of disease in the gastrointestinal
tract, and the BioJet™ systemic oral delivery platform, which is
designed to replace injection for better management of chronic
diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development and clinical
efforts and research collaboration plans and expectations are
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “might,” “will,”
“objective,” “intend,” “should,” “could,” “can,” “would,” “expect,”
“believe,” “design,” “estimate,” “predict,” “potential,” “plan,”
“target,” or the negative of these terms, and similar expressions
intended to identify forward-looking statements. These statements
reflect our plans, estimates, and expectations, as of the date of
this press release. These statements involve known and unknown
risks, uncertainties and other factors that could cause our actual
results to differ materially from the forward-looking statements
expressed or implied in this press release. Such risks,
uncertainties, and other factors include, among others, our ability
to innovate in the field of therapeutics, our ability to make
future filings and initiate clinical trials on expected timelines
or at all, our ability to obtain and maintain regulatory approval,
clearance, or acceptance of our clinical trials or products on
expected timelines or at all, our plans to research, develop, and
commercialize new products, the unpredictable relationship between
preclinical study results and clinical study results, our
expectations regarding allowed patents or intended grants to result
in issued or granted patents, our expectations regarding
opportunities with current or future pharmaceutical collaborators,
our ability to raise sufficient capital to achieve our business
objectives, and those risks described in “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in our Annual Report on Form 10-K for the
year ended December 31, 2022 filed with the SEC and other
subsequent documents, including Quarterly Reports, that we file
with the SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law. Investor ContactChuck
PadalaManaging Director, LifeSci
AdvisorsIR@bioratherapeutics.com(646) 627-8390
Media Contactmedia@bioratherapeutics.com
Biora Therapeutics (NASDAQ:BIOR)
Historical Stock Chart
From Apr 2024 to May 2024
Biora Therapeutics (NASDAQ:BIOR)
Historical Stock Chart
From May 2023 to May 2024